In a new study, researchers found that people with diabetes are at increased risk for bacterial, parasitic and viral infections.
The study illuminates how intersections of the coronavirus infection (COVID-19) and type 2 diabetes may require new approaches in treatment for hospitalized patients.
The research was conducted by a team at Mount Sinai Hospital.
Not only does the global COVID-19 pandemic have immediate implications for the therapy of type 2 diabetes, but people with obesity are also known to be at increased risk for complications arising from influenza, and obesity is emerging as important comorbidity for disease severity in the context of COVID-19.
The team reviewed how the pathophysiology of diabetes and obesity might intersect with COVID-19 biology and found key shared pathways and mechanisms linked to the development and treatment of type 2 diabetes.
Cells within the lung and gut are major sites for coronavirus entry and inflammation.
These cells express key proteins like Angiotensin-Converting Enzyme 2 (ACE2) and Dipeptidyl Peptidase-4 (DPP4) that are also present in the development of type 2 diabetes.
The team says more studies need to be done to understand the risks and benefits of commonly used diabetes medications in patients with severe coronavirus infections.
The pandemic highlights the importance of expanding innovative delivery of diabetes care and regular communication between people with diabetes and their health care providers.
The lead author of the study is Daniel J. Drucker, M.D. from Mount Sinai Hospital in Toronto.
The study is published in Endocrine Reviews.
Copyright © 2020 Knowridge Science Report. All rights reserved.
